Literature DB >> 728350

Treatment of childhood lymphocytic leukaemia with high white-cell counts.

H Ekert, K D Waters, P J Smith, R N Matthews, W M Ellis.   

Abstract

Combination chemotherapy with cytosine arabinoside, cyclophosphamide and L-asparaginase (Asnase) was given to 22 children with acute lymphocytic leukaemia (ALL) with a white-cell count greater than 30 X 10(9)/1, and other features suggestive of poor prognosis. Complete remission was induced in all patients--in 19 after 2 courses of chemotherapy and in the remainder after a third course. During induction, neutropenia occurred in 18 and severe infection in 3. Anaphylaxis to Asnase occurred in 8 patients after the second course and one other had transient Asnase-induced diabetes. All patients received central-nervous-system prophylaxis after achieving remission, during which they were also treated with weekly vincristine and a 2-week course of prednisolone. Continuation therapy consisted of short cycles of intermittent chemotherapy and BCG inoculation or long cycles of intermittent chemotherapy +/- BCG. Life-table analysis shows 46% complete remission rate at 28 months, with 6 patients all in complete remission followed up between 28 and 41 months. There were minimal complications of continuation therapy, and BCG inoculation was well tolerated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 728350      PMCID: PMC2009777          DOI: 10.1038/bjc.1978.258

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  New experimental and clinical data on leukaemia immunotherapy.

Authors:  G Mathé; L Schwarzenberg; J L Amiel; P Pouillart; M Hayat; F de Vassal; C Rosenfeld; C Jasmin
Journal:  Proc R Soc Med       Date:  1975-04

2.  Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).

Authors:  M Haghbin; C C Tan; B D Clarkson; V Miké; J H Burchenal; M L Murphy
Journal:  Cancer       Date:  1974-06       Impact factor: 6.860

3.  Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris).

Authors:  C Jacquillat; M Weil; M F Gemon; G Auclerc; J P Loisel; J Delobel; G Flandrin; G Schaison; V Izrael; A Bussel; C Dresch; C Weisgerber; D Rain; J Tanzer; Y Najean; M Seligmann; M Boiron; J Bernard
Journal:  Cancer Res       Date:  1973-12       Impact factor: 12.701

4.  Variation in survival among patients with acute lymphocytic leukemia.

Authors:  C Zippin; S J Cutler; W J Reeves; D Lum
Journal:  Blood       Date:  1971-01       Impact factor: 22.113

5.  Successful remission induction in children with acute lymphocytic leukemia at high risk for treatment failure.

Authors:  R J Aur; J V Simone; C B Pratt
Journal:  Cancer       Date:  1971-06       Impact factor: 6.860

6.  Acute leukaemia 1959-64: factors affecting prognosis.

Authors:  R M Hardisty; M M Till
Journal:  Arch Dis Child       Date:  1968-02       Impact factor: 3.791

7.  Immune function at diagnosis in relation to responses to therapy in acute lymphocytic leukemia of childhood.

Authors:  D G Jose; H Ekert; J Colebatch; K Waters; F Wilson; D O'Keefe
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

8.  Clinical importance of lymphoblasts with T markers in childhood acute leukemia.

Authors:  L Sen; L Borella
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

9.  Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results.

Authors:  S E Sallan; B M Cammita; J R Cassady; D G Nathan; E Frei
Journal:  Blood       Date:  1978-03       Impact factor: 22.113

10.  Combination chemotherapy for children with acute lymphocytic leukemia who fail to respond to standard remission-induction therapy.

Authors:  H N Lay; H Ekert; J H Colebatch
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

  10 in total
  1 in total

1.  Current management of childhood acute lymphocytic leukemia.

Authors:  H Ekert
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.